Novartis shows nail and palmoplantar psoriasis benefits of Cosentyx

Novartis has announced the findings of a new clinical trial showing how Cosentyx can benefit those affected by nail and palmoplantar psoriasis.

The GESTURE trial has offered evidence that Cosentyx can provide sustained improvements in nail and palmoplantar psoriasis for up to 2.5 years, marking the first time that any biologic has demonstrated long-term efficacy and safety for this condition.

Up to 90 percent of psoriasis patients may develop nail or palmoplantar psoriasis, which affect the palms of the hands and soles of the feet and can lead to reduced mobility, functional impairment and physical discomfort.

Cosentyx can tackle this by blocking the cornerstone cytokine interleukin-17A involved in the development and progression of psoriasis, meaning it addresses the underlying cause of the disease. It is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at five years in psoriasis.

Eric Hughes, global development unit head for immunology and dermatology at Novartis, said: "As an IL-17A inhibitor, Cosentyx provides a highly targeted treatment option that can not only effectively treat the plaques caused by psoriasis, as evident by recently presented five-year data, but also hard-to-treat forms and associated arthritic conditions."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.